🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

29+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 29 recruiting trials for “thyroid-lymphoma

Phase 2RecruitingNCT07380984

PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL

🏥 Ruijin Hospital📍 1 site📅 Started Mar 2026View details ↗
RecruitingNCT07356882

European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma

👨‍⚕️ Mathieu SIMONIN, MD, Assistance Publique - Hôpitaux de Paris📍 1 site📅 Started Nov 2025View details ↗
Phase 1, PHASE2RecruitingNCT06966154

A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

🏥 Fudan University📍 1 site📅 Started May 2025View details ↗
Phase 2RecruitingNCT07000617

A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma

🏥 Peking University Cancer Hospital & Institute📍 3 sites📅 Started Mar 2025View details ↗
Phase 1RecruitingNCT06732492

RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies

🏥 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology📍 1 site📅 Started Oct 2024View details ↗
Phase 2RecruitingNCT06848569

Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study

🏥 Sun Yat-sen University📍 1 site📅 Started Oct 2024View details ↗
Phase 2, PHASE3RecruitingNCT06563245

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

👨‍⚕️ YI JIN GAO, MD, Shanghai Children's Medical Center📍 1 site📅 Started Sep 2024View details ↗
Enrolling by InvitationNCT07450040

Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma

🏥 Eye & ENT Hospital of Fudan University📍 1 site📅 Started Sep 2024View details ↗
Phase 1, PHASE2RecruitingNCT06559553

"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL

🏥 Mingzhi Zhang📍 1 site📅 Started Sep 2024View details ↗
RecruitingNCT06796517

Immunotherapy in Lymphoma

🏥 Sung-Soo Park📍 2 sites📅 Started Jun 2024View details ↗
Phase 2RecruitingNCT06824883

Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma

🏥 Peking Union Medical College Hospital📍 1 site📅 Started May 2024View details ↗
Phase 1, PHASE2RecruitingNCT06376721

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

👨‍⚕️ Liang Wang, M.D., Beijing Tongren Hospital📍 1 site📅 Started Apr 2024View details ↗
Phase 1RecruitingNCT06060782

Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine

🏥 Fifth Affiliated Hospital, Sun Yat-Sen University📍 1 site📅 Started Mar 2024View details ↗
Phase 2RecruitingNCT04838652

Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

👨‍⚕️ Andreas Engert, Prof., 1st Department of Medicine, Cologne Universit Hospital📍 1 site📅 Started Mar 2024View details ↗
Phase 2RecruitingNCT06314334

Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma

👨‍⚕️ Rong Tao, MD, Fudan Cancer Hospital📍 6 sites📅 Started Mar 2024View details ↗
RecruitingNCT06362148

Circulating Tumor DNA in Peripheral T-cell Lymphomas

👨‍⚕️ Francesco A d'Amore, MD, DMSc, Aarhus University Hospital and Aarhus University📍 1 site📅 Started Mar 2024View details ↗
NARecruitingNCT06069830

PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma

🏥 Ruijin Hospital📍 1 site📅 Started Dec 2023View details ↗
Phase 2RecruitingNCT05900765

A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

👨‍⚕️ Zhiming Li, Sun Yat-sen University📍 1 site📅 Started Jun 2023View details ↗
NARecruitingNCT05662540

PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma

🏥 Ruijin Hospital📍 1 site📅 Started May 2023View details ↗
Phase 2RecruitingNCT05833893

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

👨‍⚕️ Yu Zhao, Graduate, Chief📍 1 site📅 Started May 2023View details ↗
Page 1 of 2Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →